
News|Articles|December 1, 2012
Escitalopram reduces the risk of depression in patients with HCV treated with interferon alpha
Pre-emptive therapy with the selective serotonin reuptake inhibitor escitalopram in patients initiating interferon therapy for hepatitis C virus (HCV) without psychiatric risk factors reduced the risk of depression, according to a recent study published in the Annals of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5

























